

Neurosurgery for the Hospitalist

2021-2024

References

1. Suarez JI. Diagnosis and Management of Subarachnoid Hemorrhage. *Continuum (Minneap Minn)*. 2015;21(5 Neurocritical Care):1263-1287.
2. Al-Mufti F, Mayer SA. Neurocritical Care of Acute Subdural Hemorrhage. *Neurosurg Clin N Am*. 2017;28(2):267-278.
3. Tenny S, Thorell W. Intracranial Hemorrhage. In: *StatPearls*. Treasure Island (FL)2020.
4. Karibe H, Hayashi T, Hirano T, Kameyama M, Nakagawa A, Tominaga T. Surgical management of traumatic acute subdural hematoma in adults: a review. *Neurol Med Chir (Tokyo)*. 2014;54(11):887-894.
5. Phan K, Moore JM, Griessenauer C, et al. Craniotomy Versus Decompressive Craniectomy for Acute Subdural Hematoma: Systematic Review and Meta-Analysis. *World Neurosurg*. 2017;101:677-685 e672.
6. Yang W, Huang J. Chronic Subdural Hematoma: Epidemiology and Natural History. *Neurosurg Clin N Am*. 2017;28(2):205-210.
7. Lawton MT, Vates GE. Subarachnoid Hemorrhage. *N Engl J Med*. 2017;377(3):257-266.
8. Ziu E, Mesfin FB. Subarachnoid Hemorrhage. In: *StatPearls*. Treasure Island (FL)2021.
9. Etminan N, Chang HS, Hackenberg K, et al. Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage According to Region, Time Period, Blood Pressure, and Smoking Prevalence in the Population: A Systematic Review and Meta-analysis. *JAMA Neurol*. 2019;76(5):588-597.
10. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2012;43(6):1711-1737.
11. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. *J Neurosurg*. 1968;28(1):14-20.
12. Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. *J Neurosurg*. 1988;68(6):985-986.
13. Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. *Lancet*. 2005;366(9488):809-817.

14. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. *Crit Care Med*. 2006;34(3):617-623; quiz 624.
15. Marcolini E, Stretz C, DeWitt KM. Intracranial Hemorrhage and Intracranial Hypertension. *Emerg Med Clin North Am*. 2019;37(3):529-544.
16. Cusack TJ, Carhuapoma JR, Ziai WC. Update on the Treatment of Spontaneous Intraparenchymal Hemorrhage: Medical and Interventional Management. *Curr Treat Options Neurol*. 2018;20(1):1.
17. Balami JS, Buchan AM. Complications of intracerebral haemorrhage. *Lancet Neurol*. 2012;11(1):101-118.
18. Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2014;85(6):660-667.
19. Hemphill JC, 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2015;46(7):2032-2060.
20. Kuramatsu JB, Biffi A, Gerner ST, et al. Association of Surgical Hematoma Evacuation vs Conservative Treatment With Functional Outcome in Patients With Cerebellar Intracerebral Hemorrhage. *JAMA*. 2019;322(14):1392-1403.
21. de Oliveira Manoel AL, Goffi A, Zampieri FG, et al. The critical care management of spontaneous intracranial hemorrhage: a contemporary review. *Crit Care*. 2016;20:272.
22. Rosenfelder N, Khoo V. Brain metastases. *BMJ Clin Evid*. 2011;2011.
23. McNeill KA. Epidemiology of Brain Tumors. *Neurol Clin*. 2016;34(4):981-998.
24. Perkins A, Liu G. Primary Brain Tumors in Adults: Diagnosis and Treatment. *Am Fam Physician*. 2016;93(3):211-217.
25. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. *Neuro Oncol*. 2019;21(Suppl 5):v1-v100.
26. Wong JM, Panchmatia JR, Ziewacz JE, et al. Patterns in neurosurgical adverse events: intracranial neoplasm surgery. *Neurosurg Focus*. 2012;33(5):E16.
27. Carlson ML, Link MJ, Wanna GB, Driscoll CL. Management of sporadic vestibular schwannoma. *Otolaryngol Clin North Am*. 2015;48(3):407-422.
28. Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. *Am Fam Physician*. 2013;88(5):319-327.
29. Li A, Liu W, Cao P, Zheng Y, Bu Z, Zhou T. Endoscopic Versus Microscopic Transsphenoidal Surgery in the Treatment of Pituitary Adenoma: A Systematic Review and Meta-Analysis. *World Neurosurg*. 2017;101:236-246.

30. Lobatto DJ, de Vries F, Zamanipoor Najafabadi AH, et al. Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. *Pituitary*. 2018;21(1):84-97.
31. Rosenow F, McCarthy V, Caruso AC. Sleep apnoea in endocrine diseases. *J Sleep Res*. 1998;7(1):3-11.
32. Ehrlich GE. Back pain. *J Rheumatol Suppl*. 2003;67:26-31.
33. Buchbinder R, van Tulder M, Oberg B, et al. Low back pain: a call for action. *Lancet*. 2018;391(10137):2384-2388.
34. Snyder DL, Doggett D, Turkelson C. Treatment of degenerative lumbar spinal stenosis. *Am Fam Physician*. 2004;70(3):517-520.
35. Gibson J, Nouri A, Krueger B, et al. Degenerative Cervical Myelopathy: A Clinical Review. *Yale J Biol Med*. 2018;91(1):43-48.
36. Carette S, Fehlings MG. Clinical practice. Cervical radiculopathy. *N Engl J Med*. 2005;353(4):392-399.
37. Glotzbecker MP, Bono CM, Wood KB, Harris MB. Postoperative spinal epidural hematoma: a systematic review. *Spine (Phila Pa 1976)*. 2010;35(10):E413-420.
38. Al-Mutair A, Bednar DA. Spinal epidural hematoma. *J Am Acad Orthop Surg*. 2010;18(8):494-502.
39. Amiri AR, Fouyas IP, Cro S, Casey AT. Postoperative spinal epidural hematoma (SEH): incidence, risk factors, onset, and management. *Spine J*. 2013;13(2):134-140.
40. Babu JM, Patel SA, Palumbo MA, Daniels AH. Spinal Emergencies in Primary Care Practice. *Am J Med*. 2019;132(3):300-306.
41. Swann MC, Hoes KS, Aoun SG, McDonagh DL. Postoperative complications of spine surgery. *Best Pract Res Clin Anaesthesiol*. 2016;30(1):103-120.
42. N. ERGASISL. *Principles of Neurological Surgery*. 3rd ed. Philadelphia, PA: Elsevier; 2012.
43. Leinonen V, Vanninen R, Rauramaa T. Cerebrospinal fluid circulation and hydrocephalus. *Handb Clin Neurol*. 2017;145:39-50.
44. Martin-Laez R, Caballero-Arzapalo H, Lopez-Menendez LA, Arango-Lasprilla JC, Vazquez-Barquero A. Epidemiology of Idiopathic Normal Pressure Hydrocephalus: A Systematic Review of the Literature. *World Neurosurg*. 2015;84(6):2002-2009.
45. van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. *Brain*. 2001;124(Pt 2):249-278.
46. Kowalski RG, Claassen J, Kreiter KT, et al. Initial misdiagnosis and outcome after subarachnoid hemorrhage. *JAMA*. 2004;291(7):866-869.

47. Stevens RD, Shoykhet M, Cadena R. Emergency Neurological Life Support: Intracranial Hypertension and Herniation. *Neurocrit Care*. 2015;23 Suppl 2:S76-82.
48. Munakomi S, J MD. Brain Herniation. In: *StatPearls*. Treasure Island (FL)2021.
49. Koenig MA. Cerebral Edema and Elevated Intracranial Pressure. *Continuum (Minneapolis)*. 2018;24(6):1588-1602.
50. Flanagan EP, Pittock SJ. Diagnosis and management of spinal cord emergencies. *Handb Clin Neurol*. 2017;140:319-335.
51. Khan AA, Jabbar A, Banerjee A, Hinchley G. Cerebrospinal shunt malfunction: recognition and emergency management. *Br J Hosp Med (Lond)*. 2007;68(12):651-655.
52. Greenberg MS. *Handbook of Neurosurgery*. 9th ed. New York, NY: Thieme; 2020.
53. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. *Clin Infect Dis*. 2017;64(6):e34-e65.
54. Pelegrin I, Lora-Tamayo J, Gomez-Junyent J, et al. Management of Ventriculoperitoneal Shunt Infections in Adults: Analysis of Risk Factors Associated With Treatment Failure. *Clin Infect Dis*. 2017;64(8):989-997.
55. Schmidt JM, Ko SB, Helbok R, et al. Cerebral perfusion pressure thresholds for brain tissue hypoxia and metabolic crisis after poor-grade subarachnoid hemorrhage. *Stroke*. 2011;42(5):1351-1356.
56. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. *Stroke*. 2010;41(10):2391-2395.
57. Budohoski KP, Guilfoyle M, Helmy A, et al. The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry*. 2014;85(12):1343-1353.
58. Wong GK, Nung RC, Sitt JC, et al. Location, Infarct Load, and 3-Month Outcomes of Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage. *Stroke*. 2015;46(11):3099-3104.
59. Francoeur CL, Mayer SA. Management of delayed cerebral ischemia after subarachnoid hemorrhage. *Crit Care*. 2016;20(1):277.
60. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev*. 2007(3):CD000277.
61. Veldeman M, Hollig A, Clusmann H, Stevanovic A, Rossaint R, Coburn M. Delayed cerebral ischaemia prevention and treatment after aneurysmal

- subarachnoid haemorrhage: a systematic review. *Br J Anaesth.* 2016;117(1):17-40.
62. Saber H, Desai A, Palla M, Mohamed W, Seraji-Bozorgzad N, Ibrahim M. Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. *J Stroke Cerebrovasc Dis.* 2018;27(11):2979-2985.
 63. Muehlschlegel S. Subarachnoid Hemorrhage. *Continuum (Minneap Minn).* 2018;24(6):1623-1657.
 64. Li K, Barras CD, Chandra RV, et al. A Review of the Management of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage. *World Neurosurg.* 2019;126:513-527.
 65. Rosenthal ES, Biswal S, Zafar SF, et al. Continuous electroencephalography predicts delayed cerebral ischemia after subarachnoid hemorrhage: A prospective study of diagnostic accuracy. *Ann Neurol.* 2018;83(5):958-969.
 66. Dankbaar JW, Slooter AJ, Rinkel GJ, Schaaf IC. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. *Crit Care.* 2010;14(1):R23.
 67. Gathier CS, van den Bergh WM, van der Jagt M, et al. Induced Hypertension for Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Randomized Clinical Trial. *Stroke.* 2018;49(1):76-83.
 68. Hannon MJ, Finucane FM, Sherlock M, Agha A, Thompson CJ. Clinical review: Disorders of water homeostasis in neurosurgical patients. *J Clin Endocrinol Metab.* 2012;97(5):1423-1433.
 69. Fraser JF, Stieg PE. Hyponatremia in the neurosurgical patient: epidemiology, pathophysiology, diagnosis, and management. *Neurosurgery.* 2006;59(2):222-229; discussion 222-229.
 70. Robertson GL. Disorders of the Neurohypophysis. In: Jameson JLFASKDLHSLDLLJ, ed. *Harrison's Principles of Internal Medicine.* 20th ed. New York, NY: McGraw-Hill; 2018.
 71. Kelly DF, Laws ER, Jr., Fossett D. Delayed hyponatremia after transsphenoidal surgery for pituitary adenoma. Report of nine cases. *J Neurosurg.* 1995;83(2):363-367.
 72. Tenny S, Thorell W. Cerebral Salt Wasting Syndrome. In: *StatPearls.* Treasure Island (FL)2020.
 73. Baek SH, Jo YH, Ahn S, et al. Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial. *JAMA Intern Med.* 2021;181(1):81-92.
 74. Esposito D, Olsson DS, Ragnarsson O, Buchfelder M, Skoglund T, Johannsson G. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. *Pituitary.* 2019;22(4):422-434.

75. Semple PL, Laws ER, Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. *J Neurosurg.* 1999;91(2):175-179.
76. Singer PA, Sevilla LJ. Postoperative endocrine management of pituitary tumors. *Neurosurg Clin N Am.* 2003;14(1):123-138.
77. Witherspoon B, Ashby NE. The Use of Mannitol and Hypertonic Saline Therapies in Patients with Elevated Intracranial Pressure: A Review of the Evidence. *Nurs Clin North Am.* 2017;52(2):249-260.
78. Wijdicks EF, Sheth KN, Carter BS, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2014;45(4):1222-1238.
79. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. *Neurosurgery.* 2017;80(1):6-15.
80. Changa AR, Czeisler BM, Lord AS. Management of Elevated Intracranial Pressure: a Review. *Curr Neurol Neurosci Rep.* 2019;19(12):99.
81. Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. *Neurocrit Care.* 2020;32(3):647-666.
82. Hinson HE, Stein D, Sheth KN. Hypertonic saline and mannitol therapy in critical care neurology. *J Intensive Care Med.* 2013;28(1):3-11.
83. Sandercock PA, Soane T. Corticosteroids for acute ischaemic stroke. *Cochrane Database Syst Rev.* 2011(9):CD000064.
84. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. *Lancet.* 2000;355(9203):542-545.
85. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemc patterns in patients receiving prednisolone for COPD. *J Clin Endocrinol Metab.* 2011;96(6):1789-1796.
86. Australian Pift, New Zealand Intensive Care Society Clinical Trials Group AHSCCSCN, the Irish Critical Care Trials G, et al. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. *JAMA.* 2020;323(7):616-626.
87. Lim-Fat MJ, Bi WL, Lo J, et al. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. *Neurosurgery.* 2019;85(3):E607-E608.
88. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin Immunol.* 2013;9(1):30.

89. Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. *Ann Intern Med.* 2020;173(5):325-330.
90. Corry JJ. The use of targeted temperature management for elevated intracranial pressure. *Curr Neurol Neurosci Rep.* 2014;14(6):453.
91. Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. *N Engl J Med.* 2015;373(25):2403-2412.
92. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. *Ann Intern Med.* 1994;120(11):897-902.
93. Sjoblom L, Hardemark HG, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. *Stroke.* 2001;32(11):2567-2574.
94. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. *Stroke.* 2012;43(6):1511-1517.
95. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet.* 2014;383(9921):955-962.
96. Frontera JA, Lewin JJ, 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. *Neurocrit Care.* 2016;24(1):6-46.
97. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. *Stroke.* 2006;37(6):1465-1470.
98. Hanger HC, Geddes JA, Wilkinson TJ, Lee M, Baker AE. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. *Intern Med J.* 2013;43(3):308-316.
99. Frontera JA, Gordon E, Zach V, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. *Neurocrit Care.* 2014;21(3):397-406.
100. Hill R, Han TS, Lubomirova I, Math N, Bentley P, Sharma P. Prothrombin Complex Concentrates are Superior to Fresh Frozen Plasma for Emergency Reversal of Vitamin K Antagonists: A Meta-Analysis in 2606 Subjects. *Drugs.* 2019;79(14):1557-1565.

101. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA*. 2015;313(8):824-836.
102. Steiner T, Poli S, Griebel M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. *Lancet Neurol*. 2016;15(6):566-573.
103. Full prescribing information for PRAXBIND. <https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf>. Updated 4/2018. Accessed 2/22/2021, 2021.
104. Full Prescribing Information for ANDEXXA. <https://www.fda.gov/media/113279/download>. Updated 12/2018. Accessed 11/25/2020, 2020.
105. Pollack CV, Jr., Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. *N Engl J Med*. 2017;377(5):431-441.
106. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med*. 2019;380(14):1326-1335.
107. Frontera JA, Bhatt P, Lalchan R, et al. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. *J Thromb Thrombolysis*. 2020;49(1):121-131.
108. Panos NG, Cook AM, John S, Jones GM, Neurocritical Care Society Pharmacy Study G. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. *Circulation*. 2020;141(21):1681-1689.
109. Ohm C, Mina A, Howells G, Bair H, Bendick P. Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage. *J Trauma*. 2005;58(3):518-522.
110. Lee AT, Gagnidze A, Pan SR, et al. Preoperative Low-Dose Aspirin Exposure and Outcomes After Emergency Neurosurgery for Traumatic Intracranial Hemorrhage in Elderly Patients. *Anesth Analg*. 2017;125(2):514-520.
111. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. *Lancet*. 2016;387(10038):2605-2613.
112. Li X, Sun Z, Zhao W, et al. Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage. *J Neurosurg*. 2013;118(1):94-103.
113. Naidech AM, Maas MB, Levasseur-Franklin KE, et al. Desmopressin improves platelet activity in acute intracerebral hemorrhage. *Stroke*. 2014;45(8):2451-2453.

114. Kapapa T, Rohrer S, Struve S, et al. Desmopressin acetate in intracranial haemorrhage. *Neurol Res Int.* 2014;2014:298767.
115. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. *J Am Coll Cardiol.* 2017;69(7):871-898.
116. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e326S-e350S.
117. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 2017;135(25):e1159-e1195.
118. Croci DM, Kamenova M, Guzman R, Mariani L, Soleman J. Novel Oral Anticoagulants in Patients Undergoing Cranial Surgery. *World Neurosurg.* 2017;105:841-848.
119. Palmer JD, Sparrow OC, Iannotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. *Neurosurgery.* 1994;35(6):1061-1064; discussion 1064-1065.
120. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2016;68(10):1082-1115.
121. Forster MT, Mathe AK, Senft C, Scharrer I, Seifert V, Gerlach R. The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. *J Clin Neurosci.* 2010;17(8):975-979.
122. Aspegren OP, Astrand R, Lundgren MI, Romner B. Anticoagulation therapy a risk factor for the development of chronic subdural hematoma. *Clin Neurol Neurosurg.* 2013;115(7):981-984.
123. Guha D, Coyne S, Macdonald RL. Timing of the resumption of antithrombotic agents following surgical evacuation of chronic subdural hematomas: a retrospective cohort study. *J Neurosurg.* 2016;124(3):750-759.
124. Kamenova M, Lutz K, Schaedelin S, Fandino J, Mariani L, Soleman J. Does Early Resumption of Low-Dose Aspirin After Evacuation of Chronic Subdural Hematoma With Burr-Hole Drainage Lead to Higher Recurrence Rates? *Neurosurgery.* 2016;79(5):715-721.

125. Rahman M, Donnangelo LL, Neal D, Mogali K, Decker M, Ahmed MM. Effects of Perioperative Acetyl Salicylic Acid on Clinical Outcomes in Patients Undergoing Craniotomy for Brain Tumor. *World Neurosurg.* 2015;84(1):41-47.
126. Hanalioglu S, Sahin B, Sahin OS, et al. Effect of perioperative aspirin use on hemorrhagic complications in elective craniotomy for brain tumors: results of a single-center, retrospective cohort study. *J Neurosurg.* 2019;132(5):1529-1538.
127. Cheng A, Poon MTC, Demetriades AK. Aspirin therapy discontinuation and intraoperative blood loss in spinal surgery: a systematic review. *Neurosurg Rev.* 2018;41(4):1029-1036.
128. Cuellar JM, Petrizzo A, Vaswani R, Goldstein JA, Bendo JA. Does aspirin administration increase perioperative morbidity in patients with cardiac stents undergoing spinal surgery? *Spine (Phila Pa 1976).* 2015;40(9):629-635.
129. Skukalek SL, Winkler AM, Kang J, et al. Effect of antiplatelet therapy and platelet function testing on hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the pipeline embolization device: a review and meta-analysis. *J Neurointerv Surg.* 2016;8(1):58-65.
130. Zakeri AS, Nimjee SM. Use of Antiplatelet Agents in the Neurosurgical Patient. *Neurosurg Clin N Am.* 2018;29(4):517-527.
131. Ryu CW, Park S, Shin HS, Koh JS. Complications in Stent-Assisted Endovascular Therapy of Ruptured Intracranial Aneurysms and Relevance to Antiplatelet Administration: A Systematic Review. *AJNR Am J Neuroradiol.* 2015;36(9):1682-1688.
132. Texakalidis P, Bekelis K, Atallah E, Tjoumakaris S, Rosenwasser RH, Jabbour P. Flow diversion with the pipeline embolization device for patients with intracranial aneurysms and antiplatelet therapy: A systematic literature review. *Clin Neurol Neurosurg.* 2017;161:78-87.
133. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. *Circulation.* 2015;132(6):517-525.
134. Li YG, Lip GYH. Anticoagulation Resumption After Intracerebral Hemorrhage. *Curr Atheroscler Rep.* 2018;20(7):32.
135. Newman TV, Chen N, He M, Saba S, Hernandez I. Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010-2016. *Am J Cardiovasc Drugs.* 2020;20(5):471-479.
136. Majeed A, Kim YK, Roberts RS, Holmstrom M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. *Stroke.* 2010;41(12):2860-2866.
137. Becattini C, Sembolini A, Paciaroni M. Resuming anticoagulant therapy after intracerebral bleeding. *Vascul Pharmacol.* 2016;84:15-24.

138. Ding X, Liu X, Tan C, et al. Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: A meta-analysis of cohort studies. *J Neurol Sci.* 2018;384:133-138.
139. Birkeland P, Lauritsen J, Poulsen FR. Aspirin is associated with an increased risk of subdural hematoma in normal-pressure hydrocephalus patients following shunt implantation. *J Neurosurg.* 2015;123(2):423-426.
140. Berger A, Constantini S, Ram Z, Roth J. Acute subdural hematomas in shunted normal-pressure hydrocephalus patients - Management options and literature review: A case-based series. *Surg Neurol Int.* 2018;9:238.
141. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. *J Clin Oncol.* 2006;24(8):1310-1318.
142. Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. *Blood.* 2015;126(4):494-499.
143. Lin RJ, Green DL, Shah GL. Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis. *Oncologist.* 2018;23(4):468-473.
144. Cote DJ, Dubois HM, Karhade AV, Smith TR. Venous Thromboembolism in Patients Undergoing Craniotomy for Brain Tumors: A U.S. Nationwide Analysis. *Semin Thromb Hemost.* 2016;42(8):870-876.
145. Constantini S, Kanner A, Friedman A, et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. *J Neurosurg.* 2001;94(6):918-921.
146. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. *J Thromb Haemost.* 2010;8(9):1959-1965.
147. Nyquist P, Bautista C, Jichici D, et al. Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Evidence-Based Guideline: A Statement for Healthcare Professionals from the Neurocritical Care Society. *Neurocrit Care.* 2016;24(1):47-60.
148. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med.* 1998;339(2):80-85.
149. Alshehri N, Cote DJ, Hulou MM, et al. Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis. *J Neurooncol.* 2016;130(3):561-570.
150. Kim J, Gearhart MM, Zurick A, Zuccarello M, James L, Luchette FA. Preliminary report on the safety of heparin for deep venous thrombosis prophylaxis after severe head injury. *J Trauma.* 2002;53(1):38-42; discussion 43.

151. Lacut K, Bressollette L, Le Gal G, et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. *Neurology*. 2005;65(6):865-869.
152. Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. *J Thromb Haemost*. 2011;9(5):893-898.
153. Licci M, Kamenova M, Guzman R, Mariani L, Soleman J. Influence of Postoperative Thrombosis Prophylaxis on the Recurrence of Chronic Subdural Hematoma After Burr-Hole Drainage. *Crit Care Med*. 2018;46(1):e26-e32.
154. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e601S-e636S.
155. Yoshioka K, Murakami H, Demura S, Kato S, Tsuchiya H. Prevalence and risk factors for development of venous thromboembolism after degenerative spinal surgery. *Spine (Phila Pa 1976)*. 2015;40(5):E301-306.
156. Schroeder GD, Hilibrand AS, Arnold PM, et al. Epidural Hematoma Following Cervical Spine Surgery. *Global Spine J*. 2017;7(1 Suppl):120S-126S.
157. Khan NR, Patel PG, Sharpe JP, Lee SL, Sorenson J. Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis. *J Neurosurg*. 2018;129(4):906-915.
158. Kepler CK, McKenzie J, Kreitz T, Vaccaro A. Venous Thromboembolism Prophylaxis in Spine Surgery. *J Am Acad Orthop Surg*. 2018;26(14):489-500.